Ibrutinib Impurity SYGIM is a specific degradation or process-related impurity associated with Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor used in the treatment of B-cell malignancies. This impurity serves as a reference standard in pharmaceutical quality control, enabling the detection, identification, and quantification of trace levels in drug substance and formulations to ensure compliance with regulatory purity standards such as those from ICH guidelines. It is utilized in analytical methods like HPLC and LC-MS for impurity profiling during drug development and manufacturing.